Redox/pH dual stimuli-responsive ZnO QDs-gated mesoporous silica nanoparticles as carriers in cancer therapy

Surface-modified, zinc-incorporated mesoporous silica nanoparticles with improved antibacterial and rapid hemostatic properties

Severe bleeding and bacterial infections pose significant challenges to the global public health. Effective hemostatic materials have the potential to be used for rapid control of bleeding at the wound site. In this study, mesoporous silica nanoparticles (MSN) were doped with zinc ions (MSN@Zn) and subsequently functionalized with carboxyl (-COOH) groups through post-grafting, resulting in (MSN@Zn-COOH). The results demonstrated the successful functionalization of carboxyl groups on the surface of MSN@Zn mesoporous materials with minimal impact on the morphology. The released zinc ions showed potent antibacterial activity (above ∼80 %) against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus). In vitro and in vivo assessments of MSN@Zn-COOH revealed excellent hemostatic effects and favorable blood compatibility. Hemolysis percentages associated with MSN@Zn-COOH exhibited noteworthy reductions in comparison to MSN. Furthermore, a decrease in APTT (a test evaluating the intrinsic coagulation pathway) of modified MSN@Zn indicated enhanced hemostasis, supported by their negative zeta potential (∼ -14 to -43 mV). Importantly, all samples showed no cytotoxicity. This work underscores the potential of MSN@Zn-COOH, with its combined hemostatic performance and antibacterial activity, for emergency clinical applications.

Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect

Due to the theragnostic potential of mesoporous silica nanoparticles (MSNs), these were extensively investigated as a novel approach to improve clinical outcomes. Boasting an impressive array of formulations and modifications, MSNs demonstrate significant in vivo efficacy when used to identify or treat myriad malignant diseases in preclinical models. As MSNs continue transitioning into clinical trials, a thorough understanding of the characteristics of effective MSNs is necessary. This review highlights recent discoveries and advances in MSN understanding and technology. Specific focus is given to cancer theragnostic approaches using MSNs. Characteristics of MSNs such as size, shape, and surface properties are discussed in relation to effective nanomedicine practice and projected clinical efficacy. Additionally, tumor-targeting options used with MSNs are presented with extensive discussion on active-targeting molecules. Methods for decreasing MSN toxicity, improving site-specific delivery, and controlling release of loaded molecules are further explained. Challenges facing the field and translation to clinical environments are presented alongside potential avenues for continuing investigations.

The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis

Atherosclerosis (AS) as the leading cause of cardiovascular and cerebrovascular events has been paid much attention all the time. With the continuous development of modern medical drug treatment, surgical treatment, interventional treatment and other methods, the mortality rate of AS has shown a downward trend, while the morbidity rate is still increasing. Oral lipid-lowering or anti-inflammatory drugs are generally used for early AS, but the relatively low accumulation efficiency in lesions and the unavoidable side effects required researchers to develop more effective drug delivery approaches for the therapy of AS. Mesoporous silica nanoparticles as nanocarrier for drug delivery have received extensive attentions due to their flexible size, high specific surface area, controlled pore volume, high drug loading capacity and excellent biocompatibility. Series of good reviews about the mesoporous silica nanoparticles loaded drugs for cancer therapy have been well documented. However, their roles as nanocarrier for drug delivery to treat AS have few reports. In this review, the applications and challenges of mesoporous silica nanomaterials in the field of the diagnosis and therapy of AS have been summarized. The classification, synthesis, formation mechanism, surface modification and functionalization of mesoporous silica nanomaterials which were closely related to the theranostic effect of AS have also been included. Last but not the least, the future prospects’ suggestions of mesoporous silica nanomaterial-based drug delivery system for AS are also provided.

Progress in Mesoporous Silica Nanoparticles as Drug Delivery Agents for Cancer Treatment

Cancer treatment and therapy have made significant leaps and bounds in these past decades. However, there are still cases where surgical removal is impossible, metastases are challenging, and chemotherapy and radiotherapy pose severe side effects. Therefore, a need to find more effective and specific treatments still exists. One way is through the utilization of drug delivery agents (DDA) based on nanomaterials. In 2001, mesoporous silica nanoparticles (MSNs) were first used as DDA and have gained considerable attention in this field. The popularity of MSNs is due to their unique properties such as tunable particle and pore size, high surface area and pore volume, easy functionalization and surface modification, high stability and their capability to efficiently entrap cargo molecules. This review describes the latest advancement of MSNs as DDA for cancer treatment. We focus on the fabrication of MSNs, the challenges in DDA development and how MSNs address the problems through the development of smart DDA using MSNs. Besides that, MSNs have also been applied as a multifunctional DDA where they can serve in both the diagnostic and treatment of cancer. Overall, we argue MSNs provide a bright future for both the diagnosis and treatment of cancer.

Protein adsorption on spark plasma sintered 2d-, 3d- and lamellar type mesoporous silicate compacts

The preparation of lamellar type mesoporous silica (MPS) compact through the spark plasma sintering (SPS) and the adsorption/desorption of protein onto MPS compact are reported to be compared with those onto 2d-hexagonal and 3d-cubic type MPS compacts. A lamellar-type MPS powder (MPS-la) was prepared using triblock copolymer, PEO5PPO68PEO5, and was compacted in a carbon die and heated at 500°C for 5 min under uniaxial pressure. The products are referred to as MPS-la-500. The MPS compacts keep the lamellar type mesoporous configuration. The adsorbed amount of protein onto MPS-la-500 was 100 mg/g, while that on MPS-la was 130 mg/g, and the former decreased by 23%. However, its decreasing ratio of the protein adsorption on MPS-la-500 was less than those of 2d-hexagonal and 3d-cubic type MPS compacts, which were 73 and 34%, respectively. The released amount of protein into PBS solution from MPS-la-500, which was soaked in the protein solution for 48 h, increased with the soaking time, while those from 2d- and 3d-type MPS compacts reached to plateau for 4 h of soaking. The lamellar type MPS compact was found to be easier to absorb and release proteins, which may be due to the large aperture of the mesoporous configuration.